Overview

IGF-1 Therapy in Patients With Cystic Fibrosis

Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
28 week pilot study to examine the efficacy of recombinant human IGF-1 on body weight and composition in adults with cystic fibrosis.
Phase:
Phase 1
Details
Lead Sponsor:
Stony Brook University
Treatments:
Mecasermin